MAXWELL USA LLC JOINS USUBC
First New Member for 2008, Member No. 53
USUBC, Washington, DC
January 8, 2008
The executive committee of the U.S.-Ukraine Business Council
(USUBC) is pleased to announce that MaxWell USA, LLC, a
Washington, D.C.-based medical/pharmaceutical company, has been
(USUBC) is pleased to announce that MaxWell USA, LLC, a
Washington, D.C.-based medical/pharmaceutical company, has been
approved as the first new member for 2008 and as the 53rd member
of USUBC.
USUBC has been meeting with Dr. Peter M. Leitner, President of
USUBC has been meeting with Dr. Peter M. Leitner, President of
MaxWell USA, and with Alex Meerovich, Public Relations Manager,
since early December 2007 about MaxWell's strong interest in being a
member of USUBC. Dr. Leitner will represent MaxWell USA on
the USUBC board of directors.
As a U.S. company with a growing presence in Ukraine, MaxWell USA
As a U.S. company with a growing presence in Ukraine, MaxWell USA
is working to meet significant unmet medical needs in the emerging
markets of the former Soviet Union, including through on-site production
of high-tech, high-quality bio- and chemopharmaceuticals targeting
oncological and cardiological diseases.
The head office is based in downtown DC, but the bulk of their current
activity is in Ukraine, where MaxWell is building a large, state of the art
pharmaceutical production facility in the town of Boryspil, just outside
Kyiv.
Once completed, the Boryspil facility will employ around 500 people
and will produce a range of bio- and chemo-pharmaceuticals in a variety
of formats. Production is slated to begin in 2008.
The company president is Dr. Ken Alibek, noted American microbiologist,
biotechnologist, and biodefense expert originally from Kazakhstan. Dr.
Alibek currently divides his time between MaxWell's corporate head-
The head office is based in downtown DC, but the bulk of their current
activity is in Ukraine, where MaxWell is building a large, state of the art
pharmaceutical production facility in the town of Boryspil, just outside
Kyiv.
Once completed, the Boryspil facility will employ around 500 people
and will produce a range of bio- and chemo-pharmaceuticals in a variety
of formats. Production is slated to begin in 2008.
The company president is Dr. Ken Alibek, noted American microbiologist,
biotechnologist, and biodefense expert originally from Kazakhstan. Dr.
Alibek currently divides his time between MaxWell's corporate head-
quarters in Washington, D.C. and the Boryspil facility.
Their plans for Ukraine include much more than manufacturing and
distributing pharmaceuticals. MaxWell is also establishing a network of
out-patient clinics across Ukraine (the first clinic in Boryspil opened on
August 1, 2007); they just published in Kyiv the first issue of their
popular-medical journal, "Science, Health, Life"; and they plan to open a
specialized cancer and cardiology clinic, a drug development center, a
clinical studies center, and a diagnostic and clinical center, all in close
proximity to the Boryspil plant.
In short, MaxWell is creating a novel and comprehensive healthcare
complex in and around Kyiv to realize the corporate motto: "We Help
You Live Longer."
The corporate website is www.max-well.com, available in Ukrainian,
Russian and English.
Their plans for Ukraine include much more than manufacturing and
distributing pharmaceuticals. MaxWell is also establishing a network of
out-patient clinics across Ukraine (the first clinic in Boryspil opened on
August 1, 2007); they just published in Kyiv the first issue of their
popular-medical journal, "Science, Health, Life"; and they plan to open a
specialized cancer and cardiology clinic, a drug development center, a
clinical studies center, and a diagnostic and clinical center, all in close
proximity to the Boryspil plant.
In short, MaxWell is creating a novel and comprehensive healthcare
complex in and around Kyiv to realize the corporate motto: "We Help
You Live Longer."
The corporate website is www.max-well.com, available in Ukrainian,
Russian and English.